SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community members discuss its potential connection to Panasonic's recently announced solid-state battery development and the implications for Tesla, fueled by existing partnerships and shared board members. Investors are speculating on a potential partnership announcement given recent milestones, insider activity, and the broader shift towards solid-state battery technology. The community is closely watching for news that could drive the stock higher, with some drawing comparisons to past surges.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

Brera Holdings PLC ($BREA) is trending as traders discuss its shift to a Solana-based digital asset treasury named Solmate, fueled by a substantial $300 million private investment. The community is focused on the potential for significant gains, drawing comparisons to other crypto-related stocks that have experienced massive surges. Bullish sentiment is countered by some concerns about potential dilution and the sustainability of the pump.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as it approaches all-time highs, fueled by bullish sentiment around potential interest rate cuts and possible inclusion in the S&P 500. The community is actively discussing the stock's breakout potential, while also weighing the possibility of profit-taking after a significant run-up. Optimistic investors are highlighting long-term growth prospects and management's strategic vision, while short-term traders eye potential volatility around upcoming announcements.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending as the stock continues to decline despite having beat earnings and maintained guidance, leading to frustration and speculation of market manipulation among investors. Community members are debating whether to buy the dip, hold long-term, or cut losses, with some pointing to potential catalysts like future election ad revenue or a possible acquisition. Concerns about competition from walled gardens like Amazon and a recent analyst downgrade are also contributing to the negative sentiment.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx ($FDX) is trending following an earnings beat, though community sentiment is mixed due to a weaker-than-expected outlook and caution around tariffs. Discussions revolve around whether cost-cutting can offset potential headwinds and if the post-earnings dip presents a buying opportunity or signals deeper concerns. Traders are also watching the stock in relation to competitors like UPS and Amazon.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses its partnerships and real-world applications within the payroll and payment sectors. Recent focus is on their progress with regulatory compliance and anticipation for potential exchange listings. Community members are actively discussing staking and long-term potential, drawing comparisons to other established crypto projects.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the impact of recently ended tariff exemptions and potential for a dividend cut, despite a high current yield. Some traders are noting technical indicators suggesting a possible bottom, while others point to insider buying as a positive sign. Overall, community sentiment appears mixed as traders assess whether the current price reflects underlying economic concerns or presents a value opportunity.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar Corp. is trending following its Q3 earnings report, which revealed that the company missed expectations amidst ongoing housing market pressures. Community discussions are focused on the lowered guidance and potential impact of interest rates and inflation on the housing market, while some suggest that this may be a buying opportunity. The news is impacting the broader homebuilder sector, with attention on how Lennar's results reflect the overall health of the housing market.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending amid discussions around the cancellation of Jimmy Kimmel's show, sparking debates about free speech and cancel culture from both conservative and liberal viewpoints. The community is divided, with some calling for boycotts and others defending Disney's decision, creating volatility in the stock. Broader concerns include the company's handling of streaming services and its response to political pressures.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending following positive three-year data from its Phase 1 trial of Lonvo-z for hereditary angioedema, showing a significant reduction in attack rates. The community is discussing the potential for this to be a one-time treatment and is speculating about a short squeeze due to high short interest and potential acquisition interest from larger pharmaceutical companies.  Some traders are also citing positive technical indicators and potential sector rotation into biotech.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Tyra Biosciences (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors PR Newswire CARLSBAD, Calif., Jan. 29, 2025...

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) Tyra Biosciences Receives IND Clearance from FDA to Proceed...

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences to Present at Upcoming Investor Conferences Tyra Biosciences to Present at Upcoming Investor Conferences PR Newswire CARLSBAD, Calif., Nov. 13, 2024 CARLSBAD, Calif., Nov. 13, 2024...

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights PR Newswire CARLSBAD, Calif., Nov. 7, 2024...

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) Tyra Biosciences Receives IND Clearance from FDA to Proceed with...

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial...

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET Tyra Biosciences to Host Conference Call on Interim Clinical...

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical data for TYRA-300 and increased sales projections for metastatic urothelial...

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Tyra Biosciences Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.50	--	--	N/A
Q2 '25	-$0.53	-$0.47	11.22%	BEAT
Q1 '25	-$0.49	-$0.47	3.25%	BEAT
Q4 '24	-$0.47	-$0.43	9.25%	BEAT
Q3 '24	-$0.40	-$0.41	-2.82%	MISSED

TYRA
Tyra Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TYRA News

TYRA Tyra Biosciences Inc